1.
Support Care Cancer
; 17(4): 465-8, 2009 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19037666
RESUMO
INTRODUCTION: Imatinib mesylate is a tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) throughout all the phases of the disease. In most cases, this drug is well tolerated; however, some cases experience side effects. RESULTS AND DISCUSSION: Skin rashes and oral lesions are uncommon and appear to be dose-dependent. The authors report two cases of CML Ph+ in chronic phase patients who presented skin and oral lesions probably induced by imatinib therapy.